Icahn School of Medicine at Mount Sinai
This randomized, single-blinded, sham-controlled trial evaluates whether a single injection of autologous platelet-rich plasma (PRP) into the distal anterior vaginal wall improves sexual function in women with sexual dysfunction. Sixty participants with a Female Sexual Function Index (FSFI) total score of 26.5 or lower are randomized 1:1 to PRP injection or sterile saline injection. Sexual function, sexual distress, global impression of change, and urinary incontinence symptoms are assessed at baseline, 6 weeks, and 6 months after injection.
Participants complete baseline questionnaires at screening, followed by an in-person injection visit. All participants undergo a 40 mL whole blood draw to preserve blinding. For participants randomized to PRP, the blood is processed using a double-spin centrifugation protocol; for participants randomized to the control arm, the blood sample is discarded. Then 4 cc of PRP or sterile saline is injected with a 25-gauge needle just deep to the vaginal epithelium of the distal anterior vaginal wall, approximately 3 cm from the urethral meatus. Procedural pain is recorded before speculum insertion,…
Inclusion Criteria: * Female, 18 years of age or older, presenting with sexual dysfunction * FSFI total score ≤ 26.5 * English speaking and literate Exclusion Criteria: * Unwilling or unable to provide informed consent * Pregnant or less than 12 weeks postpartum * Known history of bleeding disorder
Whole blood draw of 40 mL is processed by double-spin centrifugation; 4 cc PRP is injected with a 25-guage needle just deep to the epithelium of the distal anterior vaginal wall, about 3 cm from the urethral meatus, after topical lidocaine.
4-5cc sterile saline injected at the same location, depth, and technique as the PRP arm, following a blood draw.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.